A Cochrane systematic review (2022, 57 trials, N=30,058) found that semaglutide 1 mg reduced HbA1c by a mean of 1.46 percentage points versus placebo in type 2 diabetes [12]
von Websky K, Reichetzeder C, Hocher B
With advances in genetic testing technology, it is possible to more accurately diagnose monogenic diabetes and provide individualized treatment for non-obese diabetic patients (Murphy et al., 2023)
The NO pathway is especially important in endothelial cells, as PKA activates NO synthase (NOS), which can produce more nitric acid and does result in reduced small intestine, large intestine, and colon motility
who observed decreased SOD activity in paediatric patients with CD remission (37)
Last reviewed 2026-07-03